Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six
presentations at the American Heart Association (AHA) Scientific
Sessions 2020, taking place online from November 13, 2020 –
November 17, 2020, including the presentation of primary results
from GALACTIC-HF (
Global
Approach
to
Lowering
Adverse
Cardiac Outcomes
Through
Improving
Contractility in
Heart
Failure), the Phase 3 event
driven cardiovascular outcomes clinical trial of omecamtiv
mecarbil, in a Late Breaking Clinical Trial session, as well as
five poster presentations.
Results from GALACTIC-HF, one of the largest
heart failure trials ever conducted, will be presented at a live,
virtual, embargoed AHA News Briefing on Thursday, November 12, 2020
from 1:30-2:30 PM CT.
Late Breaking Clinical Trial
Session
Title: Omecamtiv Mecarbil in Chronic Heart Failure With
Reduced Ejection Fraction: The Global Approach to Lowering Adverse
Cardiac Outcomes Through Improving Contractility in Heart Failure
(GALACTIC-HF) Trial Session: LBS.01 -
Heart Failure and Atrial Fibrillation: Vitamins, Minerals,
Nutrients, and MoreSpeaker: John Teerlink, M.D.,
Professor of Medicine, University of California San Francisco,
Director of Heart Failure, San Francisco Veterans Affairs Medical
Center and Executive Committee Chair,
GALACTIC-HFDate: November 13,
2020Presentation Time: 10:35 – 10:45 AM CT
Cytokinetics Investor/Media
Event
Cytokinetics will host an investor/media event
related to the results of GALACTIC-HF on November 13, 2020 at 1:00
PM ET that will be simultaneously webcast and can be accessed at
https://wsw.com/webcast/cc/cytk/1388034 or by visiting the
Investors & Media section of Cytokinetics’ website at
www.cytokinetics.com. An archived replay of the virtual event will
be available via Cytokinetics’ website until November 13,
2021. Members of Cytokinetics’ senior management will be joined by
the following physician experts:
- John Teerlink,
M.D., Professor of Medicine, University of California San
Francisco, Director of Heart Failure, San Francisco Veterans
Affairs Medical Center and Executive Committee Chair,
GALACTIC-HF
- G. Michael Felker,
M.D., M.H.S, Professor of Medicine, Vice-Chief of
Cardiology for Clinical Research, Duke University School of
Medicine and Director of Cardiovascular Research, Duke Clinical
Research Institute
- Scott Solomon,
M.D., Edward D. Frohlich Distinguished Chair, Professor of
Medicine, Harvard Medical School and Director of Noninvasive
Cardiology, Brigham and Women's Hospital
- Nihar R. Desai, M.D.,
MPH, Associate Professor of Medicine, Associate Chief,
Cardiovascular Medicine, Yale School of Medicine, Center for
Outcomes Research and Evaluation
ePosters On Demand
The following posters will be available on
demand from the start of the conference on November 13, 2020 at
9:00 AM CT until the end of the conference on November 17, 2020,
8:30 PM CT.
Title: The Cardiac Myosin Inhibitor,
CK-3772271, Attenuates Cardiac Fibrosis and Diastolic Dysfunction
in the Dahl/Salt Sensitive Rat Model of Heart Failure With
Preserved Ejection FractionSession:
MP.APS.05 - Heart Failure IPresenter: Darren Hwee,
Ph.D., Associate Director, Pharmacology, Cytokinetics
Poster Number: P1762
Title: Pharmacodynamic Effects of a
Single Dose of CK-3773274 in Cats With Hypertrophic
Cardiomyopathy Session: CE.APS.01 -
Protein Dysfunction in Heart FailurePresenter:
Joshua Stern, D.V.M., Ph.D., Associate Professor & Chief of
Service: Cardiology, School of Veterinary Medicine, University of
California, DavisPoster Number: P756
Title: Demographic and Clinical
Characteristics of Patients With Obstructive Hypertrophic
Cardiomyopathy in a Large, Nationwide Us
CohortSession: HF.APS.29 - Different
Aspects of Hypertrophic Cardiomyopathy Presenter:
Michael Butzner, MPH, CCRP, HEOR Consultant,
CytokineticsPoster Number: P1735
Title: Thirty Day Episode of Care
Spending Following Heart Failure Hospitalization Among Medicare
Beneficiaries With Heart FailureSession:
HF.APS.17 - Heart Failure Quality of Care and Process
ImprovementPresenter: Nihar R. Desai, M.D., MPH,
Yale University School of Medicine Poster Number:
P975
Title: Characteristics and Outcomes of
Patients With Heart Failure With Reduced Ejection Fraction and a
Worsening Heart Failure EventSession:
HF.APS.11 - Acute and Advanced Heart
FailurePresenter: Anthony P. Carnicelli, M.D.,
Duke Clinical Research Institute – DCRIPoster
Number: P427
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF, of which topline results were recently reported, and
METEORIC-HF, which is ongoing. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is developing reldesemtiv, a
fast skeletal muscle troponin activator (FSTA) for the potential
treatment of ALS and other neuromuscular indications following
conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The
company is considering potential advancement of reldesemtiv to
Phase 3 pending ongoing regulatory interactions. Cytokinetics is
collaborating with Astellas Pharma Inc. (Astellas) to research,
develop and commercialize other novel mechanism skeletal sarcomere
activators (not including FSTAs). Licenses held by Amgen and
Astellas are subject to specified co-development and
co-commercialization rights of Cytokinetics. Cytokinetics is also
developing CK-274, a novel cardiac myosin inhibitor that company
scientists discovered independent of its collaborations, for the
potential treatment of hypertrophic cardiomyopathies. Cytokinetics
has granted Ji Xing Pharmaceuticals Limited an exclusive license to
develop and commercialize CK-274 in China and Taiwan, in accordance
with Cytokinetics’ planned global registration programs.
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics continues its
over 20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to the GALACTIC-HF clinical trial,
including the results thereof; statements relating to the
METEORIC-HF clinical trial; the potential benefits
of omecamtiv mecarbil, including its ability to represent a
novel therapeutic strategy to increase cardiac muscle function and
restore cardiac performance; the timing and likelihood of
regulatory approval for omecamtiv mecarbil, Cytokinetics' and
its partners' research and development activities; the design,
timing, results, significance and utility of preclinical and
clinical results; and the properties and potential benefits
of Cytokinetics' other drug candidates. Such statements
are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in
the development, testing, regulatory approvals for trial
commencement, progression or product sale or manufacturing, or
production of Cytokinetics' drug candidates that could
slow or prevent clinical development or product
approval; Cytokinetics' drug candidates may have adverse
side effects or inadequate therapeutic efficacy; the FDA or foreign
regulatory agencies may delay or limit Cytokinetics' or
its partners' ability to conduct clinical
trials; Cytokinetics may be unable to obtain or maintain
patent or trade secret protection for its intellectual property;
the nature of Amgen's decisions with respect to the design,
initiation, conduct, timing and continuation of development
activities for omecamtiv mecarbil; standards of care may
change, rendering Cytokinetics' drug candidates obsolete;
competitive products or alternative therapies may be developed by
others for the treatment of
indications Cytokinetics' drug candidates and potential
drug candidates may target; and risks and uncertainties relating to
the timing and receipt of payments from its partners, including
milestones and royalties on future potential product sales
under Cytokinetics' collaboration agreements with such
partners. For further information regarding these and other risks
related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities
and Exchange Commission.
Contact:CytokineticsDiane WeiserSenior Vice
President, Corporate Communications, Investor Relations(415)
290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024